Antares Pharma stock is heating up as the stock had a Resurrection Cross last week of the 50 day MA crossing above the 200 day MA.
I’m thinking when Antares Pharma reports earnings next, it’s going to be awesome because on February 14, 2018 the FDA approved AMAG’s Makena, a subcutaneous injection for pre-term birth. Several benefits from the new method of administration are a faster injection with a less painful, concealed needle in the arm. The previous generation of Makena required a multi-step process involving a 21-gauge, 1.5 inch needle and a 60 second plus injection duration in the gluteus maximus. The simpler and less painful process for subcutaneous Makena, with no expected increase in price, will result in a rapid switch over to the new product and limited resistance from payors. First sales were recognized in the last week in March which was the end of the quarter for reporting. On the next earnings report, we’ll have a full 3 months of sales and that could really add to Antares Pharma’s revenue growth.
I’m thinking the FDA will approve the epinephrine pen but there has been no indication from the FDA or guidance by Teva on approval or launch of these products.
I first profiled this stock to Premium members back on January 28, 2018 in an article entitled Antares Pharma PDUFA On Rising Large Players Volume. Since then, ATRS is up 21.6%.
Disclosure: I do not hold any position in ATRS stock.